抗小鼠CTLA-4单抗(9D9)在4T1乳腺癌模型中怎么给药?

a Group mean TV from treatment initiation on Day 10 through end of study on Day 34. n = 10 mice/group. All animals survived through Day 34 with exception of one animal in untreated group which exited study on Day 32. SPD suspensions (40 mg/mL) and vehicle were dosed IT on Days 10, 14, 18, and 22 (red triangles). Anti-mCTLA-4 (10 mg/kg) was dosed IP on Days 10, 13, 17, and 20 (black diamonds). The combination group received both SPD and anti-mCTLA-4 on the same schedules as the monotreatments. b Group mean percent change in body weight from treatment initiation on Day 10 through end of study on Day 34. Error bars =  ± SEM. Significance reported for Day 34 versus untreated/vehicle controls; ns not significant, *p 

抗小鼠CTLA-4单抗(9D9)在4T1乳腺癌模型中怎么给药?

1、用量参考

抗小鼠CTLA-4单克隆抗体(克隆号:9D9)在小鼠肿瘤模型和其他小鼠模型中通常用于体内CTLA-4中和、肿瘤内调节性T细胞耗竭等研究。9D9抗体在设计使用进行体内研究时,确定其给药的最优剂量和方案是非常重要。根据现有文献报道,我们简要总结了抗小鼠CTLA-4单抗(9D9)在4T1乳腺癌模型 (4T1 breast cancer model) 中的给药方案,仅供参考。详情如下表(注意:手机左右滑动查看完整表格):

参数 描述
动物模型 4T1乳腺癌模型
实验动物 BALB/c小鼠(雌性,6-8周龄)
给药途径 腹腔注射 (i.p.)
单只剂量 100-200 μg/只
动物数 5-10 只/组
起始时间 肿瘤接种后第3-7天
给药间隔 每3天一次
总给药次数 3-4次
对照建议 相同亚型的同型对照IgG(如小鼠IgG2b)

* 以上为常见方案范围,最佳剂量与频次需结合动物状态与实验目的优化。

2、参考文献

1.Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer. Pack CD, et al. Human Vaccines & Immunotherapeutics. 2020 Jun;16(12):3184-3193. doi: 10.1080/21645515.2020.1754691. PMID: 32530786

2.Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer. Schofield DJ, et al. mAbs. 2021 Jan;13(1):1857100. doi: 10.1080/19420862.2020.1857100. PMID: 33397194

3.CTLA-4 Blockade in Tumor Models: An Overview of Preclinical and Translational Research. Grosso JF, et al. Cancer Immunity. 2013 Jan;13:5. doi: Not provided. PMID: 23390376

4.Regulatory T Cells Shape the Differential Impact of Radiation Dose-Fractionation Schedules on Host Innate and Adaptive Antitumor Immune Defenses. Vatner RE, et al. Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3):739-750. doi: 10.1016/j.ijrobp.2021.05.014. PMID: 34048817

5.Synthetic DNA-encoded monoclonal antibody delivery of anti-CTLA-4 antibodies induces tumor shrinkage in vivo. Duperret EK, et al. Cancer Res. 2018 Nov 15;78(22):6363-6370. doi: 10.1158/0008-5472.CAN-18-1429. PMID: 30287678

由于篇幅限制,以上仅展示了抗小鼠CTLA-4单克隆抗体(9D9)用于4T1乳腺癌模型的部分参考文献。如果您想要了解更多文献,欢迎联系我们(咨询微信:duozhaozhao2024)。

3、推荐产品

您是否在寻求价格合理、高质量的9D9抗体来推进您的研究?Syd Labs以提供体内实验级重组抗小鼠CTLA-4单克隆抗体(克隆号9D9)而闻名,如低内毒素(内毒素1 EU/mg)、极低内毒素(内毒素可低至0.05 EU/mg)、运用重组技术实现了不同分型的自由切换(小鼠版本、Fc沉默版本)。

查找Syd Labs 抗小鼠CTLA-4重组抗体(9D9)产品:抗小鼠CTLA-4单克隆抗体 (9D9)多种型

4、抗小鼠CTLA-4单抗(9D9)在不同小鼠肿瘤模型中的给药方案:

抗小鼠CTLA-4单抗(9D9)在B16黑色素瘤模型中怎么给药?
抗小鼠CTLA-4抗体(9D9)在MC38结肠腺癌模型中怎么给药?
9D9抗体在CT26结肠癌模型中怎么给药?
抗小鼠CTLA-4单抗(9D9)在Sa1N纤维肉瘤模型中怎么给药?
抗小鼠CTLA-4抗体(9D9)在EMT6乳腺癌模型中怎么给药?
9D9抗体在SW1黑色素瘤模型中怎么给药?
抗小鼠CTLA-4单抗(9D9)在TC1肺癌模型中怎么给药?
抗小鼠CTLA-4抗体(9D9)在ID8卵巢癌模型中怎么给药?
9D9抗体在胃肠道间质瘤模型中怎么给药?
抗小鼠CTLA-4单抗(9D9)在4T1乳腺癌模型中怎么给药?
抗小鼠CTLA-4抗体(9D9)在Hepa1-6肝细胞癌模型中怎么给药?
9D9抗体在不同小鼠肿瘤模型中怎么给药?